Investigational Drug Information for Alisporivir
✉ Email this page to a colleague
What is the drug development status for Alisporivir?
Alisporivir is an investigational drug.
There have been 15 clinical trials for Alisporivir.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Debiopharm International SA, Parexel, and Enanta Pharmaceuticals.
Summary for Alisporivir
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 717 |
| WIPO Patent Applications | 448 |
| Japanese Patent Applications | 264 |
| Clinical Trial Progress | Phase 3 (2011-03-01) |
| Vendors | 27 |
Recent Clinical Trials for Alisporivir
| Title | Sponsor | Phase |
|---|---|---|
| Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) | Debiopharm International SA | Phase 2 |
| Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19) | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Two-way Interaction Between Alisporivir and EDP239 | Enanta Pharmaceuticals | Phase 1 |
Clinical Trial Summary for Alisporivir
Top disease conditions for Alisporivir
Top clinical trial sponsors for Alisporivir
US Patents for Alisporivir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
